Vickers Vantage Corp. I is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
Company profile
Ticker
SCLX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Scilex Holding Company/DE, Vickers Vantage Corp. I
SEC CIK
SCLX stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
16 Apr 24
424B3
Prospectus supplement
5 Apr 24
424B3
Prospectus supplement
5 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
5 Apr 24
424B3
Prospectus supplement
2 Apr 24
424B3
Prospectus supplement
2 Apr 24
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
1 Apr 24
Latest ownership filings
3/A
Stephen Hoi Ma
12 Mar 24
SC 13D/A
SCLX Stock Acquisition JV LLC
5 Mar 24
SC 13D/A
SCLX Stock Acquisition JV LLC
31 Jan 24
4
Henry Ji
5 Oct 23
4
JAISIM SHAH
5 Oct 23
4
Yue Alexander Wu
5 Oct 23
4
Jay Chun
5 Oct 23
4
Stephen Hoi Ma
5 Oct 23
3
Henry Ji
2 Oct 23
SC 13D
SCLX Stock Acquisition JV LLC
29 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.98 mm | 1.98 mm | 1.98 mm | 1.98 mm | 1.98 mm | 1.98 mm |
Cash burn (monthly) | 11.05 mm | 41.92 k | 12.94 mm | 9.66 mm | (no burn) | 1.34 mm |
Cash used (since last report) | 73.91 mm | 280.41 k | 86.53 mm | 64.63 mm | n/a | 8.94 mm |
Cash remaining | -71.93 mm | 1.70 mm | -84.55 mm | -62.65 mm | n/a | -6.96 mm |
Runway (months of cash) | -6.5 | 40.5 | -6.5 | -6.5 | n/a | -5.2 |
Institutional ownership, Q3 2023
72.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 84 |
Opened positions | 12 |
Closed positions | 21 |
Increased positions | 17 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 39.94 bn |
Total shares | 120.09 mm |
Total puts | 233.70 k |
Total calls | 128.50 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
SCLX Stock Acquisition JV | 89.62 mm | $156.83 mm |
Vanguard | 8.08 mm | $11.31 bn |
STT State Street | 7.34 mm | $10.28 bn |
BLK Blackrock | 6.64 mm | $9.29 bn |
SRNEQ Sorrento Therapeutics | 1.92 mm | $3.36 mm |
Geode Capital Management | 931.10 k | $1.30 bn |
NTRS Northern Trust | 687.08 k | $961.91 mm |
D. E. Shaw & Co. | 627.04 k | $877.85 mm |
Rafferty Asset Management | 620.13 k | $868.18 mm |
Hudson Bay Capital Management | 474.68 k | $664.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Oct 23 | Stephen Hoi Ma | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 150,000 | 211.50 k | 150,000 |
4 Oct 23 | Jay Chun | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 250,000 | 352.50 k | 250,000 |
4 Oct 23 | Wu Yue Alexander | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 250,000 | 352.50 k | 250,000 |
4 Oct 23 | Shah Jaisim | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 200,000 | 282.00 k | 200,000 |
4 Oct 23 | Ji Henry | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 200,000 | 282.00 k | 200,000 |
News
Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
16 Apr 24
Scilex Holding Launches Co-Pay Programs For ZTlido And ELYXYB For Commercially Insured Patients And Addition Of ELYXYB To Multi-State Medicaid Pharmaceutical Purchasing Group To Purchasing Pool
9 Apr 24
Scilex Holding To Seek Approval Fro mFDA For Modification Of Gloperba To Include
20 Mar 24
Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba, Its Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024
5 Mar 24
Reported Earlier, Scilex Announces Move To Extend Lockup Period For Sorrento-Distributed Dividend Shares Until September 2024
4 Mar 24
Press releases
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
16 Apr 24
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
21 Mar 24
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
20 Mar 24
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
15 Mar 24
Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
15 Mar 24